Long-Term Follow-up of Enhanced Holter-Electrocardiography Monitoring in Acute Ischemic Stroke.

"Disclosure: The Find-AFRANDOMISED trial (NCT 01855035) was sponsored by an unrestricted research grant by Boehringer Ingelheim to the University of Göttingen, Germany.: Rolf Wachter reports having been an investigator or consultant for, or received fees from Bayer, Berlin Chemie, Bristol-Myers-Squibb, Boehringer Ingelheim, Boston Scientific, CVRx, Daiichi, Gilead, Johnson & Johnson, Medtronic, Novartis, Pfizer, Sanofi, Servier outside the submitted work. He received research grants from Boehringer Ingelheim, Deutsche Forschungsgemeinschaft, European Union and Bundesministerium für Bildung und Forschung (BMBF).: Mark Weber-Krüger report grants from Boehringer Ingelheim, during the conduct of the study.: Gerhard F. Hamann reports no potential conflicts of interest. Pawel Kermer reports grant and personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from Bristol-Myers Squibb outside the submitted work.: Jan Liman reports personal fees from Pfizer, Bayer Healthcare and Daiichi Sankyo outside the submitted work and grants from Boehringer Ingelheim.: Meinhard Mende reports no potential conflicts of interest.: Joachim Seegers received personal fees from Bristol-Myers Squibb outside the submitted work.: Katrin Wasser received travel compensation from Bayer.: Sonja Gröschel received travel compensation from Boehringer Ingelheim.: Timo Uphaus honoraria from Merck Serono, personal fees from Pfizer, grants from Else Kröner-Fresenius-Stiftung, outside the submitted work, outside the submitted work.: Holger Poppert reports personal fees from Bayer Healthcare, Bristol-Meyers Squipp, Daiichi Sankyo, and Pfizer outside the submitted work.: Martin Köhrmann has received honoraria and travel grants from Medtronic, BMS/Pfizer, Boehringer Ingelheim, Bayer, Novartis, Biogen, Cerevast. He received a research grant for a different study on AF detection from Boehringer Ingelheim.: Markus Zabel reports minor travel grants from Biotronik, outside the submitted work.: Ulrich Laufs reports fees for lectures from ABDA, Amgen, Ariba, AstraZeneca, Bayer, Berlin-Chemie, Boehringer, DACH, Daiichi-Sankyo, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi, Servier, Synlab.: Peter U. Heuschmann reports grants from University Göttingen (within FIND-AFRANDOMISED; FIND-AFRANDOMISED is supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), during the conduct of the study; grants from German Ministry of Research and Education, German Research Foundation, European Union, Federal Joint Committee (G-BA) within the Innovationfond, Charité-Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, grants from Charité–Universitätsmedizin Berlin (within Mondafis; Mondafis is supported by an unrestricted research grant to the Charité from Bayer), grants from University Hospital Heidelberg (within RASUNOA-prime; RASUNOA-prime is supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside the submitted work.: David Conen has received consultant or speaker fees from Servier Canada.: Klaus Gröschel reports personal fees and non-financial support from Bayer, personal fees and non-financial support and grant from Boehringer Ingelheim, personal fees from Bristol-Meyers Squipp, personal fees from Daiichi Sankyo, personal fees and non-financial support from Pfizer outside the submitted work. "

"Find-AFRANDOMISED was funded by an unrestricted research grant from Boehringer Ingelheim, Ingelheim, Germany, to the University of Göttingen, Germany. All authors guarantee the validity, accuracy and integrity of the published data. David Conen holds a McMaster University Department of Medicine Mid-Career Research Award. His work is supported by the Hamilton Health Sciences RFA Strategic Initiative Program. Disclosure: The Find-AFRANDOMISED trial (NCT 01855035) was sponsored by an unrestricted research grant by Boehringer Ingelheim to the University of Göttingen, Germany.: Rolf Wachter reports having been an investigator or consultant for, or received fees from Bayer, Berlin Chemie, Bristol-Myers-Squibb, Boehringer Ingelheim, Boston Scientific, CVRx, Daiichi, Gilead, Johnson & Johnson, Medtronic, Novartis, Pfizer, Sanofi, Servier outside the submitted work. He received research grants from Boehringer Ingelheim, Deutsche Forschungsgemeinschaft, European Union and Bundesministerium für Bildung und Forschung (BMBF).: Mark Weber-Krüger report grants from Boehringer Ingelheim, during the conduct of the study.: Gerhard F. Hamann reports no potential conflicts of interest. Pawel Kermer reports grant and personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from Bristol-Myers Squibb outside the submitted work.: Jan Liman reports personal fees from Pfizer, Bayer Healthcare and Daiichi Sankyo outside the submitted work and grants from Boehringer Ingelheim.: Meinhard Mende reports no potential conflicts of interest.: Joachim Seegers received personal fees from Bristol-Myers Squibb outside the submitted work.: Katrin Wasser received travel compensation from Bayer.: Sonja Gröschel received travel compensation from Boehringer Ingelheim.: Timo Uphaus honoraria from Merck Serono, personal fees from Pfizer, grants from Else Kröner-Fresenius-Stiftung, outside the submitted work, outside the submitted work.: Holger Poppert reports personal fees from Bayer Healthcare, Bristol-Meyers Squipp, Daiichi Sankyo, and Pfizer outside the submitted work.: Martin Köhrmann has received honoraria and travel grants from Medtronic, BMS/Pfizer, Boehringer Ingelheim, Bayer, Novartis, Biogen, Cerevast. He received a research grant for a different study on AF detection from Boehringer Ingelheim.: Markus Zabel reports minor travel grants from Biotronik, outside the submitted work.: Ulrich Laufs reports fees for lectures from ABDA, Amgen, Ariba, AstraZeneca, Bayer, Berlin-Chemie, Boehringer, DACH, Daiichi-Sankyo, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi, Servier, Synlab.: Peter U. Heuschmann reports grants from University Göttingen (within FIND-AFRANDOMISED; FIND-AFRANDOMISED is supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), during the conduct of the study; grants from German Ministry of Research and Education, German Research Foundation, European Union, Federal Joint Committee (G-BA) within the Innovationfond, Charité-Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, grants from Charité–Universitätsmedizin Berlin (within Mondafis; Mondafis is supported by an unrestricted research grant to the Charité from Bayer), grants from University Hospital Heidelberg (within RASUNOA-prime; RASUNOA-prime is supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside the submitted work.: David Conen has received consultant or speaker fees from Servier Canada.: Klaus Gröschel reports personal fees and non-financial support from Bayer, personal fees and non-financial support and grant from Boehringer Ingelheim, personal fees from Bristol-Meyers Squipp, personal fees from Daiichi Sankyo, personal fees and non-financial support from Pfizer outside the submitted work. "

"Find-AFRANDOMISED was an investigator-initiated randomized, controlled, open-label trial, conducted at four certified stroke centers in Germany. It is registered with clinicaltrials.gov (NCT01855035)."